top of page
Search

Advocating for Medication for Opioid Use Disorder

Updated: Mar 21


Advocating for Medication for Opioid Use Disorder

September 21, 2022 Leah Kuntz


The NCCHC and 166 national organizations recently signed a letter to Senate leadership advocating for increased access to buprenorphine.


The National Commission on Correctional Health Care (NCCHC) and 166 national organizations recently signed a letter to Senate leadership advocating for increased access to buprenorphine, an FDA-approved medication for opioid use disorder (OUD). They urged US Senate to pass the bipartisan Mainstreaming Addiction Treatment (MAT) Act.


For more information, visit: https://www.psychiatrictimes.com/view/advocating-for-medication-for-opioid-use-disorder


bottom of page